The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis

References

• Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol 2018;93(6):824–840. doi:10.1002/ajh.25104.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL. RAS, and RUNX1. J Clin Oncol. 2010; 28(24):3858–3865. doi:10.1200/JCO.2009.27.1361.
   PubMed Web of Science ®Google Scholar
• Geissler K, Jager E, Barna A, et al. Correlation of RAS-pathway mutations and spontaneous myeloid colony growth with progression and transformation in chronic myelomonocytic leukemia—A retrospective analysis in 337 patients. Int J Mol Sci. 2020;21:3025, doi:10.3390/ijms21083025.
   PubMed Web of Science ®Google Scholar
• Elmariah H, DeZern AE. Chronic myelomonocytic leukemia: 2018 update to prognosis and treatment. Curr Hematol Malig Rep. 2019;14(3):154–163. doi:10.1007/s11899-019-00509-9.
   PubMed Web of Science ®Google Scholar
• Mora E, Sanz GF. Current management of patients with chronic myelomonocytic leukemia. Curr Opin Oncol. 2018;30(6):409–417. doi:10.1097/CCO.0000000000000486.
   PubMed Web of Science ®Google Scholar
• Harada Y, Harada H. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment]. Rinsho Ketsueki. 2016;57(2):147–155. doi:10.11406/rinketsu.57.147.
   PubMedGoogle Scholar
• Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e393, doi:10.1038/bcj.2016.5.
   PubMed Web of Science ®Google Scholar
• Feng Y, Li X, Cassady K, et al. Tet2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol. 2019;9:210, doi:10.3389/fonc.2019.00210.
   PubMed Web of Science ®Google Scholar
• Yamazaki J, Taby R, Vasanthakumar A, et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics. 2012;7(2):201–207. doi:10.4161/epi.7.2.19015.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144–147. doi:10.1182/blood-2009-03-210039.
   PubMed Web of Science ®Google Scholar
• Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14):3824–3831. doi:10.1182/blood-2011-05-352039.
   PubMed Web of Science ®Google Scholar
• Fisher CL, Berger J, Randazzo F, et al. A human homolog of additional sex combs. ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. Gene. 2003; 306:115–126. doi:10.1016/s0378-1119(03)00430-x.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Muramatsu H, Makishima H, et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol 2010;150(1):83–87. doi:10.1111/j.1365-2141.2010.08196.x.
   PubMed Web of Science ®Google Scholar
• Asada S, Fujino T, Goyama S, et al. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76(13):2511–2523. doi:10.1007/s00018-019-03084-7.
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Brecqueville M, Devillier R, et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12, doi:10.1186/1756-8722-5-12.
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151(4):365–375. doi:10.1111/j.1365-2141.2010.08381.x.
   PubMed Web of Science ®Google Scholar
• Courville EL, Wu Y, Kourda J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol. 2013;26(6):751–761. doi:10.1038/modpathol.2012.218.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–2212. doi:10.1038/leu.2014.125.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Komrokji R, Cluzeau T, et al. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017;7(12):633, doi:10.1038/s41408-017-0004-0.
   PubMedGoogle Scholar
• Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–2436. doi:10.1200/JCO.2012.47.3314.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504–1510. doi:10.1038/leu.2013.88.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385, doi:10.1038/bcj.2015.113.
   PubMed Web of Science ®Google Scholar
• Palomo L, Garcia O, Arnan M, et al. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget. 2016;7(35):57021–57035. doi:10.18632/oncotarget.10937.
   PubMedGoogle Scholar
• Duchmann M, Yalniz FF, Sanna A, et al. Prognostic role of gene mutations in chronic myelomonocytic leukemia patients treated With hypomethylating agents. EBioMedicine. 2018;31:174–181. doi:10.1016/j.ebiom.2018.04.018.
   PubMed Web of Science ®Google Scholar
• Coltro G, Mangaonkar AA, Lasho TL, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia. 2020;34(5):1407–1421. doi:10.1038/s41375-019-0690-7.
   PubMed Web of Science ®Google Scholar
• McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies. JAMA. 2018;319(4):388–396. doi:10.1001/jama.2017.19163.
   PubMed Web of Science ®Google Scholar
• Cui Y, Tong H, Du X, et al. Impact of TET2. SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Exp Hematol Oncol. 2015;4:14, doi:10.1186/s40164-015-0009-y.
   PubMed Web of Science ®Google Scholar
• Niyongere S, Lucas N, Zhou JM, et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019;33(1):205–216. doi:10.1038/s41375-018-0203-0.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee KO, Park S, et al. Poor prognostic implication of ASXL1 mutations in Korean patients With chronic myelomonocytic leukemia. Ann Lab Med. 2018;38(6):495–502. doi:10.3343/alm.2018.38.6.495.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Zahid MF, Lasho TL, et al. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016;6(9):e472, doi:10.1038/bcj.2016.82.
   PubMedGoogle Scholar
• Kosmider O, Gelsi-Boyer V, Ciudad M, et al. Tet2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676–1681. doi:10.3324/haematol.2009.011205.
   PubMed Web of Science ®Google Scholar
• Cui Y, Tong H, Du X, et al. Tet2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. Stem Cell Invest. 2016;3:50, doi:10.21037/sci.2016.09.04.
   PubMedGoogle Scholar
• Armitage P, Berry G, Matthews JNS. Statistical methods in Medical research. Malden, MA: Blackwell Sci. Ltd. 2002: 583–588.
   Google Scholar
• Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116(19):3923–3932. doi:10.1182/blood-2010-03-274704.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Duchmann M, Lucas N, et al. Cmml: clinical and molecular aspects. Int J Hematol 2017;105(6):711–719. doi:10.1007/s12185-017-2243-z.
   PubMed Web of Science ®Google Scholar
• Ko M, Rao A. Tet2: epigenetic safeguard for HSC. Blood. 2011;118(17):4501–4503. doi:10.1182/blood-2011-08-373357.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25(7):1200–1202. doi:10.1038/leu.2011.58.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Adli M, LaFave LM, et al. Asxl1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180–193. doi:10.1016/j.ccr.2012.06.032.
   PubMed Web of Science ®Google Scholar
• Balasubramani A, Larjo A, Bassein JA, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun. 2015;6:7307, doi:10.1038/ncomms8307.
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41(7):838–842. doi:10.1038/ng.391.
   PubMed Web of Science ®Google Scholar
• Cimmino L, Abdel-Wahab O, Levine RL, et al. Tet family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell. 2011;9(3):193–204. doi:10.1016/j.stem.2011.08.007.
   PubMed Web of Science ®Google Scholar